Previous 10 | Next 10 |
Trial will enroll up to 180 symptomatic and pre-symptomatic participants with FTD- GRN gene mutation at multiple sites in the U.S., Europe and Australia There are currently no FDA-approved treatments for frontotemporal dementia SOUTH SAN FRANCISCO, Calif., July 24, 2020 (GLOBE N...
SOUTH SAN FRANCISCO, Calif., July 21, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the company will highlight preliminary data from a Phase 2 open-label study evaluating AL001 in individu...
Antibody-mediated engagement of TREM2 expanded unique subpopulations of metabolically active and proliferating microglia in a human TREM2 expressing mouse model of Alzheimer’s disease Chronic treatment enhanced neuroprotective microglia, reduced neuronal damage, tempered microgl...
SOUTH SAN FRANCISCO, Calif., June 03, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that members of management will participate in a virtual fireside chat at the Goldman Sachs 41 st Annual Glo...
Alector (NASDAQ: ALEC ): Q1 GAAP EPS of -$0.53 misses by $0.12 . More news on: Alector, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Provides business continuity update regarding COVID-19 Continued execution across immuno-neurology platform On track to initiate pivotal Phase 3 trial of AL001 in patients with frontotemporal dementia with a progranulin mutation (FTD-GRN) and a Phase 2 study of AL002 in Alzheime...
SOUTH SAN FRANCISCO, Calif., May 07, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Shehnaaz Suliman, M.D., MBA, M.Phil., president and chief operating officer of Alector, will present at t...
Adverum Biotechnologies (NASDAQ: ADVM ) initiated with Buy rating and $17 (36% upside) price target at Goldman Sachs. More news on: Adverum Biotechnologies, Inc., Alector, Inc., Alexion Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
A $2 trillion emergency relief package, plus a merging of Federal Reserve and Treasury functions to allow for significant quantitative easing and repo activity , is putting a floor under stocks, potentially enabling them to climb a steepening wall of worry. On March 27, I wrote an extreme...
Deals and Financings Abbisko Therapeutics, a Shanghai novel drug biopharma, raised $70 million in a Series C financing led by Singapore's Temasek. The company has four clinical programs underway, and it intends to expand its discovery pipeline, which consists of small molecule targeted oncol...
News, Short Squeeze, Breakout and More Instantly...
--INVOKE-2 is the first global Phas e 2 trial evaluating the safety and efficacy of a TREM2 agonist, AL002, in slowing disease progression in individuals with early Alzheimer’s disease (AD)-- --Baseline characteristics data for the INVOKE-2 study confirm a representative stud...
SOUTH SAN FRANCISCO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations related to the Company’s TREM2 and progranulin programs at the upcoming Alzheimer's Associatio...
SOUTH SAN FRANCISCO, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in a corporate presentation at the H.C. Wainwright 5 th Annual Neuro Pers...